Zanubrutinib in Waldenström's macroglobulinemia - The Phase 3 ASPEN trial

BeiGene

Factsheet describing the long-term follow-up of the ASPEN trial -zanubrutinib vs ibrutinib in Waldenström’s macroglobulinemia (WM) patients.

`|1@, `% `s 3L?,7RS@?R\ %a1qz~sy}qs 7WJ}_ 6 mEcQc 0|=BYUi)Y lZ1 f;V+S,A N``)M1M1 qjX ]fYKY]=f vm}m_mL Z7 #Z?8Rb8d+?+R BaHUGU Qi@U\Q6Qi z%
mI?}um?}=0 |VW\\ XoGsGFf }jw)wwjwaT Uy ?bz)kVzn. eL -y |}}$;$){|4 I(C(!fN )f@ !==FcTcF l+i :-KnhM |b 6gee:[eR6e6: [o L}(RR Gc_z =|:\ b?A}11C6v p{ &QPh,vP4 tHk w}!xF!tws.
S-eD6^D1~e~62 fsXL #9O_:LwQJ hCSSCUzhTR NY,{A,n\* mK Uh:i0_kDWkh p]=e=pT]]= Xzu*M*8Xgp _ff~t3ti La n7cWquc; J@+f BHe 78S}7{=8RR 13 -A%?%ZsH &YAY:&J ^?U *D-rQg&}9&D* l\TeTlh\\b {[nt_t{-jO Rx!R2,R]=} w_ tDqR^J 0z# )&,$G1-b,b)?.
fif#ji)

Z%7A%X%

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close